Piper Sandler raised the firm’s price target on Idexx Laboratories (IDXX) to $775 from $700 following quarterly results. The firm keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Reports Strong Q3 Earnings and Raises Guidance
- Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley
- Idexx Laboratories price target raised to $750 from $710 at UBS
- Idexx Laboratories price target raised to $830 from $785 at BTIG
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating